Lynn Durham, Stalicla CEO
Novartis offloads neurodevelopmental disorder asset to small Swiss biotech
A small Swiss biotech said it will buy a Novartis cocaine use disorder drug candidate for up to $270 million and will test it in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
